Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women

Yukio Nakamura; Takako Suzuki; Mikio Kamimura; Shota Ikegami; Kohei Murakami; Shigeharu Uchiyama; Akira Taguchi; Hiroyuki Kato

首页> 中文期刊> 《骨研究（英文版）》 >Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women

Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women

开具论文收录证明 >>

期刊封面封底目录下载 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

This randomized prospective study aimed to evaluate the clinical outcome of denosumab treatment alone and in combination with teriparatide in treatment-naive postmenopausal Japanese female patients with osteoporosis. Thirty patients were randomly assigned to two groups:(1) denosumab group(denosumab alone, n=13); and(2) combination group(denosumab+teriparatide, n=17). Serum bone-specific alkaline phosphatase(BAP), serum tartrate-resistant acid phosphatase(TRACP)-5b, urinary cross-linked N-terminal telopeptides of type I collagen(NTX), and bone mineral density(BMD) of L1–4 lumbar vertebrae(L-BMD)and bilateral total hips(H-BMD) were determined at the first visit and at various time points up to 24 months post-treatment to determine percentage changes. Serum TRACP-5b and urinary NTX were equally suppressed in both groups and maintained at low levels, with slight increases at 12, 18 and 24 months. BAP was significantly decreased in both groups from 4 to 24 months, with significant differences between the groups at 4, 8 and 15 months(P<0.05). L-BMD was significantly increased at most time points in both groups, with a significant difference between the combination group and denosumab group at 24 months(17.2% increase versus 9.6% increase; P<0.05). There was no significant difference in H-BMD between the two groups, although the levels tended to be higher in the combination group than in the denosumab group(9.5% increase versus 5.6% increase). These findings suggest that denosumab+teriparatide combination therapy may represent an important treatment for primary osteoporotic patients at high risk of vertebral fracture.

著录项

来源
《骨研究（英文版）》 |2017年第2期|152-158|共7页
作者
Yukio Nakamura; Takako Suzuki; Mikio Kamimura; Shota Ikegami; Kohei Murakami; Shigeharu Uchiyama; Akira Taguchi; Hiroyuki Kato;
展开▼
作者单位

Department of Orthopedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan;

Department of Orthopedic Surgery, Showa-Inan General Hospital, Komagane, Japan;

Department of Orthopedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan;

Center of Osteoporosis and Spinal Disorders, Kamimura Orthopaedic Clinic, Matsumoto, Japan;

Department of Orthopedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan;

Department of Orthopedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan;

Department of Orthopedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan;

Department of Oral and Maxil ofacial Radiology, Matsumoto Dental University, Shiojiri, Japan;

Department of Orthopedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan;

展开▼
原文格式 PDF
正文语种 eng
中图分类
关键词

Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women

摘要

著录项

相关主题

期刊订阅